Intra-Cellular Therapies Inc (ITCI) CEO Sells $82,087.72 in Stock

Share on StockTwits

Intra-Cellular Therapies Inc (NASDAQ:ITCI) CEO Sharon Mates sold 6,604 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $12.43, for a total value of $82,087.72. Following the completion of the transaction, the chief executive officer now owns 1,190,909 shares of the company’s stock, valued at approximately $14,802,998.87. The sale was disclosed in a document filed with the SEC, which is available at this link.

Sharon Mates also recently made the following trade(s):

  • On Friday, January 4th, Sharon Mates sold 45,598 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $11.45, for a total value of $522,097.10.
  • On Wednesday, January 2nd, Sharon Mates sold 17,478 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $11.09, for a total value of $193,831.02.

Shares of NASDAQ ITCI opened at $13.14 on Friday. The company has a market capitalization of $718.01 million, a P/E ratio of -6.20 and a beta of 1.30. Intra-Cellular Therapies Inc has a 12-month low of $10.21 and a 12-month high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.09. On average, analysts forecast that Intra-Cellular Therapies Inc will post -2.95 earnings per share for the current year.

ITCI has been the subject of several research reports. BidaskClub upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 target price on shares of Intra-Cellular Therapies in a research report on Thursday, October 4th. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Tuesday, October 16th. Leerink Swann reiterated an “outperform” rating on shares of Intra-Cellular Therapies in a research report on Friday, October 19th. Finally, ValuEngine lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Intra-Cellular Therapies presently has a consensus rating of “Buy” and a consensus price target of $27.75.

A number of institutional investors have recently made changes to their positions in ITCI. Quantbot Technologies LP raised its stake in Intra-Cellular Therapies by 5,520.7% during the 3rd quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,527 shares in the last quarter. Public Employees Retirement Association of Colorado raised its stake in Intra-Cellular Therapies by 127.8% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 5,687 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 3,190 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in Intra-Cellular Therapies during the 2nd quarter valued at $167,000. Cubist Systematic Strategies LLC raised its stake in Intra-Cellular Therapies by 53.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 3,339 shares in the last quarter. Finally, Tocqueville Asset Management L.P. raised its stake in Intra-Cellular Therapies by 42.7% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 25,060 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 7,500 shares in the last quarter. 69.53% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Intra-Cellular Therapies Inc (ITCI) CEO Sells $82,087.72 in Stock” was reported by Zolmax and is the property of of Zolmax. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://zolmax.com/investing/intra-cellular-therapies-inc-itci-ceo-sells-82087-72-in-stock/2818258.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BidaskClub Downgrades Fiesta Restaurant Group  to Strong Sell
BidaskClub Downgrades Fiesta Restaurant Group to Strong Sell
BioSpecifics Technologies  Downgraded by BidaskClub
BioSpecifics Technologies Downgraded by BidaskClub
Sportsman’s Warehouse  Stock Rating Upgraded by ValuEngine
Sportsman’s Warehouse Stock Rating Upgraded by ValuEngine
Party City Holdco  Lowered to Strong Sell at ValuEngine
Party City Holdco Lowered to Strong Sell at ValuEngine
Alliance Pharma plc  Insider Richard Jones Acquires 15,000 Shares of Stock
Alliance Pharma plc Insider Richard Jones Acquires 15,000 Shares of Stock
Richard Harpin Buys 16 Shares of Homeserve plc  Stock
Richard Harpin Buys 16 Shares of Homeserve plc Stock


Leave a Reply

 
© 2006-2019 Zolmax.